Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival-Reference-Cited by-同舟云学术

Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival

Published:2021-08 Issue: Volume:119 Page:105380
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Lien Ming-Yu,Wang Ti-Hao,Hsieh Ching-Yun,Tsai Ming-Hsui,Hua Chun-Hung,Cheng Fu-Ming,Chung Wen-Hui,Tang Chih-Hsin,Chia-Hsun Hsieh Jason

Funder

China Medical University Hospital

Ministry of Science and Technology, Taiwan

Chang Gung Memorial Hospital

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference34 articles.

1. .

2. Multifaceted mechanisms of areca nuts in oral carcinogenesis: the molecular pathology from precancerous condition to malignant transformation;Li;J Cancer,2019

3. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up;Licitra;Ann Oncol,2009

4. Outcomes of induction chemotherapy for head and neck cancer patients: a combined study of two national cohorts in Taiwan;Chen;Medicine (Baltimore),2016

5. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC;Oral Oncology;2024-06

2. Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?;Expert Review of Anticancer Therapy;2024-05-13

3. Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer;In Vivo;2024

4. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN);Oral Oncology;2023-12

5. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck;European Journal of Cancer;2023-05